海尔生物(688139) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the current reporting period was ¥555,883,780.53, a decrease of 31.15% compared to the same period last year[2]. - The net profit attributable to shareholders of the listed company was ¥78,738,439.55, down 51.06% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥64,423,011.00, reflecting a decline of 52.68% year-on-year[2]. - The basic and diluted earnings per share were both ¥0.25, a decrease of 50.98% compared to the same period last year[3]. - The company achieved a net profit of ¥357 million for the first three quarters of 2023, a year-on-year decline of 22.59%[4]. - The net profit attributable to the parent company for the third quarter was RMB 357.20 million, compared to RMB 461.45 million in the same period last year, reflecting a decrease of approximately 22.5%[39]. - The total comprehensive income for the third quarter was RMB 335.13 million, down from RMB 466.76 million year-on-year, indicating a decline of about 28.1%[39]. - The company reported a net profit of 365,645,845.17 yuan for the current period, down from 464,543,504.50 yuan in the previous period[64]. Revenue Breakdown - The life sciences segment generated revenue of ¥835 million, with core business revenue decreasing by 0.64% year-on-year[21]. - In the first three quarters of 2023, the company achieved operating revenue of RMB 1.826 billion, with a core business revenue growth of 11.35% after excluding the public health prevention business from the same period last year[54]. - The medical innovation segment achieved revenue of 986 million yuan in the first three quarters, with core business growing by 24.02% year-on-year[71]. - Domestic market revenue for the first three quarters reached CNY 1.21 billion, with core business growth of 17.15% year-on-year[84]. - Overseas market revenue for the first three quarters was CNY 608 million, showing a year-on-year growth of 1.05%, primarily impacted by project order delivery delays[84]. Research and Development - The total R&D investment was ¥85,076,764.84, an increase of 9.95% year-on-year, accounting for 15.3% of operating revenue[3]. - R&D, sales, and management expense ratios increased compared to the same period last year, due to the discontinuation of public health prevention business and increased R&D investment[72]. - The net profit after deducting non-recurring gains and losses decreased by 52.68% year-on-year, as the company increased R&D investment and market expansion efforts[58]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥167,496,285.23, a decrease of 13.45% compared to the same period last year[2]. - The company's total current assets as of September 30, 2023, amounted to RMB 2.64 billion, a decrease from RMB 3.49 billion at the end of 2022, representing a decline of approximately 24.4%[45]. - Cash and cash equivalents at the end of the third quarter of 2023 amounted to approximately CNY 1.28 billion, an increase from CNY 748.47 million at the end of the same period in 2022[81]. - The net cash flow from investing activities for the first three quarters of 2023 was approximately CNY 352.97 million, a significant improvement from a negative CNY 16.34 million in the same period of 2022[81]. - The company reported a total of CNY 4.65 billion in cash received from investment recoveries in the first three quarters of 2023, down from CNY 9.68 billion in the same period of 2022[81]. - The company’s total cash inflow from financing activities for the first three quarters of 2023 was CNY 8.40 million, compared to CNY 24.27 million in the same period of 2022[81]. Assets and Equity - The total assets as of September 30, 2023, were ¥5,492,366,972.02, a slight increase of 0.06% from the end of the previous year[12]. - The equity attributable to shareholders of the listed company was ¥4,207,513,559.88, up 4.65% from the end of the previous year[12]. - Total liabilities amounted to 1,075,023,932.18 yuan, a decrease from 1,340,645,397.33 yuan in the previous period[63]. - Total equity attributable to shareholders of the parent company increased to 4,207,513,559.88 yuan from 4,020,637,920.82 yuan in the previous period[63]. Future Outlook - The company plans to continue focusing on innovation and cost efficiency to drive future growth and improve profitability[54]. - The company is actively responding to macroeconomic challenges and is committed to enhancing its core business performance in the upcoming quarters[54]. - The company maintained a sufficient backlog of orders as of the end of the reporting period, indicating a stable outlook for future revenue generation[84].